Literature DB >> 22591383

Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy.

Michele Dal Bo1, Riccardo Bomben, Antonella Zucchetto, Giovanni Del Poeta, Gianluca Gaidano, Silvia Deaglio, Dimitar G Efremov, Valter Gattei.   

Abstract

Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease characterized by the accumulation/expansion of a clonal population of small mature B lymphocytes in blood, bone marrow, and lymphoid organs. Although initial genetic events are considered primarily responsible for the first step(s) of neoplastic transformation, the development and progression of the CLL clone are thought to be affected by various micro-environmental signals that regulate proliferation and survival of malignant B cells. In the present review, we focus on specific interactions of CLL cells with the microenvironmental component, as they occur through the usage by CLL cells of specific molecular structures whose expression has been associated with prognosis, including: i) interactions of CLL cells via the surface BCR and dependent on specific molecular features of the BCR itself and/or the presence of the BCR-associated molecule ZAP- 70; ii) non-BCR-dependent proliferative and/or pro-survival interactions of CLL cells by CD49d and CD38. An overview of the putative drugs that could be employed to target specific molecules involved in CLL cells/tumor microenvironment interactions is also proposed in the closing chapter of the review.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22591383     DOI: 10.2174/138161212801227078

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  8 in total

Review 1.  Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.

Authors:  Ting-Ting Han; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2013-10-22       Impact factor: 4.742

2.  TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.

Authors:  Patricia K A Mongini; Rashmi Gupta; Erin Boyle; Jennifer Nieto; Hyunjoo Lee; Joanna Stein; Jela Bandovic; Tatjana Stankovic; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

3.  Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.

Authors:  Sarah E M Herman; Rashida Z Mustafa; Jade Jones; Deanna H Wong; Mohammed Farooqui; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-06-18       Impact factor: 12.531

Review 4.  Sequencing of chronic lymphocytic leukemia therapies.

Authors:  Jacqueline C Barrientos
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  Management of Chronic Lymphocytic Leukemia in the Elderly.

Authors:  Jacqueline C Barrientos
Journal:  Cancer Control       Date:  2015-10       Impact factor: 3.302

Review 6.  Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

Authors:  Yair Herishanu; Ben-Zion Katz; Andrew Lipsky; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2013-04       Impact factor: 3.722

7.  Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.

Authors:  Irene Amigo-Jiménez; Elvira Bailón; Noemí Aguilera-Montilla; María José Terol; José A García-Marco; Angeles García-Pardo
Journal:  Oncotarget       Date:  2015-12-29

Review 8.  Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review.

Authors:  Francesco Autore; Paolo Strati; Luca Laurenti; Alessandra Ferrajoli
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.